Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether other drugs like it would similarly struggle in testing.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.